BCDA
BioCardia, Inc.·Healthcare
1.18
0.855%(+0.01)
Market ClosedLast Updated: — ET
52W L: $1.0052W H: $3.20
BCDA NEWS
businesswire.com
Mar 30
Tamboran Farmout Pilot Area and BCDA Acreage for Significant Premium in Acreage Value
NEW YORK--(BUSINESS WIRE)--Tamboran Resources Corporation (NYSE: TBN, ASX: TBN): Tamboran Resources Corporation Chief Executive Officer, Mr. Todd Abbott, said: “This transaction represents a significant validation of the underlying value of our Beetaloo acreage with an implied valuation well above our recent traded metrics. Importantly, it allows us to accelerate activity while preserving balance sheet strength and maintaining operatorship of our core assets. “The INPEX investment in the Beetal.
defenseworld.net
Mar 26
BioCardia Q4 Earnings Call Highlights
BioCardia (NASDAQ: BCDA) executives on Tuesday outlined new clinical data for the company's lead cell therapy program and discussed upcoming regulatory interactions in the U.S. and Japan, while also reviewing full-year 2025 financial results. Programs and target indication Chief Executive Officer Peter Altman said BioCardia is focused on cardiovascular disease using three primary platforms: the CardiAMP
seekingalpha.com
Mar 24
BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript
BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript
globenewswire.com
Mar 24
BioCardia Reports 2025 Business Highlights and Financial Results
SUNNYVALE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2025 and filed its annual report on Form 10-K with the Securities and Exchange Commission.
globenewswire.com
Mar 19
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the year ended December 31, 2025 by conference call on Tuesday, March 24, 2026 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session.
defenseworld.net
Mar 19
BioCardia (NASDAQ:BCDA) Stock Price Down 3.9% – Time to Sell?
Shares of BioCardia, Inc. (NASDAQ: BCDA - Get Free Report) fell 3.9% on Wednesday. The company traded as low as $1.22 and last traded at $1.23. 42,279 shares traded hands during mid-day trading, a decline of 44% from the average session volume of 75,777 shares. The stock had previously closed at $1.28. Analyst Ratings Changes
